Loading...
XNAS
DVAX
Market cap1.36bUSD
Jul 25, Last price  
11.36USD
1D
1.79%
1Q
4.99%
Jan 2017
187.59%
IPO
-87.38%
Name

Dynavax Technologies Corp

Chart & Performance

D1W1MN
P/E
49.95
P/S
4.92
EPS
0.23
Div Yield, %
—
Shrs. gr., 5y
13.11%
Rev. gr., 5y
51.08%
Revenues
277m
+19.36%
14,655,0004,847,00014,093,00037,094,00040,318,00023,950,00021,614,0009,714,00011,251,00011,032,0004,050,00011,043,000327,0008,198,00035,219,00046,551,000439,442,000722,683,000232,284,000277,246,000
Net income
27m
P
-20,555,000-52,052,000-59,971,000-20,829,000-30,565,000-57,308,000-48,597,000-69,949,000-66,720,000-90,722,000-106,794,000-112,444,000-95,154,000-158,899,000-151,397,000-91,776,00076,713,000293,156,000-6,389,00027,309,000
CFO
67m
-33.86%
-22,858,000-37,240,000-32,032,000-17,035,000-33,552,000-51,370,000-47,116,000-43,809,000-58,673,000-73,738,000-92,559,000-107,051,000-77,518,000-131,301,000-121,252,000-92,251,000335,528,00062,716,000100,563,00066,512,000
Earnings
Aug 04, 2025

Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
URL
https://www.dynavax.com/
IPO date
Feb 19, 2004
Employees
351
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
277,246
19.36%
232,284
-67.86%
722,683
64.45%
Cost of revenue
231,923
257,999
440,161
Unusual Expense (Income)
NOPBT
45,323
(25,715)
282,522
NOPBT Margin
16.35%
39.09%
Operating Taxes
3,546
2,022
1,143
Tax Rate
7.82%
0.40%
NOPAT
41,777
(27,737)
281,379
Net income
27,309
-527.44%
(6,389)
-102.18%
293,156
282.15%
Dividends
Dividend yield
Proceeds from repurchase of equity
(100,000)
6,360
9,639
BB yield
5.87%
-0.35%
-0.60%
Debt
Debt current
4,496
3,631
Long-term debt
276,630
286,634
290,811
Deferred revenue
Other long-term liabilities
60,581
60,411
384
Net debt
(437,204)
(451,172)
(330,160)
Cash flow
Cash from operating activities
66,512
100,563
62,716
CAPEX
(6,352)
(4,104)
(7,139)
Cash from investing activities
(18,035)
(153,928)
(315,995)
Cash from financing activities
(102,017)
1,386
19,525
FCF
45,398
61,048
132,875
Balance
Cash
713,834
742,302
624,395
Long term investments
207
Excess cash
699,972
730,688
588,468
Stockholders' equity
(907,872)
(932,562)
(929,505)
Invested Capital
1,815,494
1,871,959
1,768,912
ROIC
2.27%
16.20%
ROCE
4.99%
33.66%
EV
Common stock shares outstanding
133,344
128,733
150,797
Price
12.77
-8.66%
13.98
31.39%
10.64
-24.38%
Market cap
1,702,803
-5.38%
1,799,687
12.17%
1,604,480
-14.26%
EV
1,265,599
1,348,515
1,274,320
EBITDA
53,375
(18,439)
289,190
EV/EBITDA
23.71
4.41
Interest
6,794
6,757
6,732
Interest/NOPBT
14.99%
2.38%